Inovio Achieves Third Cancer Indication Milestone for MEDI0457...
PLYMOUTH MEETING, Pennsylvania, Apr. 8, 2019 /PRNewswire-AsiaNet/-- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it achieved a third indication milestone from AstraZeneca resulting from dosing a patient in a Phase 2 combination trial evaluating MEDI0457 (formerly called INO-3112) in combination ...
Authors: LATEST ASIANET NEWS RELEASES